
Iambic Therapeutics: Pioneering AI-driven drug discovery with a fast, diverse, and high-quality therapeutics pipeline.
Founded with the mission to revolutionize drug discovery, Iambic Therapeutics leverages advanced machine learning to expedite the development of high-quality therapeutics. The company combines the expertise of leading AI specialists and seasoned drug developers to create a robust platform capable of addressing various target classes and mechanisms of action. Their AI-driven software accelerates research and development, aiming to bring differentiated therapeutics to the clinic faster than traditional methods.
Iambic Therapeutics boasts a team of notable experts in artificial intelligence and pharmaceutical research, contributing to its innovative edge. The company has garnered attention for its ability to deliver clinically validated therapeutics with unprecedented speed. By integrating physics-based AI algorithms into their high-throughput experimental platform, Iambic has significantly impacted the drug discovery process, offering new molecular designs and biological insights on a weekly basis.

Seismic Therapeutic

Athos Therapeutics
athostx.com

Pathos AI
pathos.com

DeepCure
deepcure.ai

Ensem Therapeutics
ensemtx.com

Nobias Therapeutics
nobiastx.com

Terray Therapeutics
terraytx.com

TandemAI
tandemai.com

Nimble Therapeutics

Model Medicines
modelmedicines.com

Metis Therapeutics
metistx.com

Cognaisent
cognaisent.com

Superluminal Medicines
superluminalrx.com

Proxima
proximabio.com

Kimia Therapeutics
kimiatx.com
Companies similar to Iambic Therapeutics include Seismic Therapeutic, Athos Therapeutics, Pathos AI and DeepCure.
Iambic Therapeutics was founded in 2019.
Iambic Therapeutics' headquarters is located in San Diego, CA, US.
Iambic Therapeutics' most recent funding round was for $100M (USD) in October 2023.
As of Oct 3, 2023, Iambic Therapeutics has raised a total of $153M (USD).
Iambic Therapeutics has 75 employees as of Feb 5, 2024.